Cargando…

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil

This prospective, observational, open-label study aimed to provide access to ustekinumab prior to market authorization and assess its safety and effectiveness in patients with Crohn’s disease (CD) refractory to anti-tumor necrosis factor-α and conventional drugs in Brazil. Patients with a diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chebli, Julio Maria Fonseca, Parra, Rogério Serafim, Flores, Cristina, Moraes, Antonio Carlos, Nones, Rodrigo Bremer, Gomes, Tarcia Nogueira Ferreira, Perdomo, Ana Maria Bravo, Scapini, Gustavo, Zaltman, Cyrla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654680/ https://www.ncbi.nlm.nih.gov/pubmed/36362709 http://dx.doi.org/10.3390/jcm11216481

Ejemplares similares

Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
por: Zaltman, Cyrla, et al.
Publicado: (2021)

Crohn’s disease environmental factors in the developing world: A case-control study in a statewide catchment area in Brazil
por: Salgado, Valéria Cristina Loureiro, et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
por: Parra, Rogério Serafim, et al.
Publicado: (2022)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil
por: Parra, Rogerio S, et al.
Publicado: (2019)

Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil
por: Sassaki, Ligia Yukie, et al.
Publicado: (2021)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2021)

The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
por: Biancardi, Ana Luiza, et al.
Publicado: (2019)

Ophthalmic manifestations in patients with inflammatory bowel disease: A review
por: Troncoso, Leandro Lopes, et al.
Publicado: (2017)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Disease
por: Globig, Anna-Maria, et al.
Publicado: (2020)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease †
por: Bertani, Lorenzo, et al.
Publicado: (2023)

Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease
por: Dubinsky, Marla, et al.
Publicado: (2023)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis
por: Palacio, Flávia Gonçalves Musauer, et al.
Publicado: (2021)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2017)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0cjvpbihs6j54qkbm73mp103mk